Search | Clinical Trials Finder

Conditions: ITP, Immune Thrombocytopenia
Interventions: Fostamatinib; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more

Conditions: Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Interventions: RAY121; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 11
States / cities: Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more

Conditions: Bone Marrow Failure Syndromes, Anemia, Aplastic, Myelodysplastic Syndromes, Hemoglobinuria, Paroxysmal, Red-Cell Aplasia, Pure, Purpura, Thrombocytopenic, Leukemia, Lymphocytic
Interventions: Not listed
Lead sponsor: Office of Rare Diseases (ORD); NIH
Eligibility: 11 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Cleveland, Ohio + 1 more

Conditions: Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions: fostamatinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Idiopathic Thrombocytopenia Purpura
Interventions: E5501, Drug: E5501; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Immune Thrombocytopenia
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Months to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: St. Petersburg, Florida • Boston, Massachusetts

Conditions: Immune Thrombocytopenia
Interventions: PRTX-100; Drug
Lead sponsor: Protalex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Farmington Hills, Michigan + 3 more

Conditions: Immune Thrombocytopenic Purpura
Interventions: Dexamethasone USP Micronized, Prednisone; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 15 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 18
States / cities: New Orleans, Louisiana • Baltimore, Maryland • Boston, Massachusetts + 10 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Placebo, TAK-079; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: eltrombopag olamine (SB-497115-GR); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 23
States / cities: Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 20 more

Conditions: Primary Immune Thrombocytopenia
Interventions: PF-06835375; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions: Immune Globulin Intravenous (Human), 10%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 24 Months and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more

Conditions: Immune Thrombocytopenia, Platelet Disorder
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 12 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP)
Interventions: rituximab; Drug
Lead sponsor: Neufeld, Ellis J, MD, PhD; Individual
Eligibility: 18 Months to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Interventions: VLX-1005, Placebo; Drug
Lead sponsor: Veralox Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 9 more

Conditions: Immune Thrombocytopenia
Interventions: Avatrombopag, Placebo; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Long Beach, California • Orange, California + 18 more

Conditions: Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Interventions: Romiplostim; Biological
Lead sponsor: Amgen; Industry
Eligibility: 1 Year and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 24
States / cities: Orange, California • San Diego, California • Washington D.C., District of Columbia + 20 more

Conditions: Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Interventions: KZR-616; Drug
Lead sponsor: Kezar Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Jacksonville, Florida + 12 more

Conditions: Immune Thrombocytopenic Purpura
Interventions: LGD-4665, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: San Diego, California • San Francisco, California • Manchester, Connecticut + 9 more

Conditions: Immune Thrombocytopenia
Interventions: Acetaminophen and Diphenhydramine Only Product; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Immune Thrombocytopenia
Interventions: Avatrombopag Oral Tablet; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Blinded (placebo), Open Label (Avatrombopag tablets), Blinded (Avatrombopoag tablets); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: Anaheim, California • Bakersfield, California • Manchester, Connecticut + 8 more

Search by objective public record fields.

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Identifying Characteristics of Bone Marrow Failure Syndromes

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

Initial Treatment of Patients With Immune Thrombocytopenic Purpura

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

EXTEND (Eltrombopag Extended Dosing Study)

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Safety and Efficacy of Eltrombopag at Escalated Doses

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

Post IVIG Medication in Children With Immune Thrombocytopenia

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003